Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316160 · ClinicalTrials.gov registry record · Phase 4
Sexual Functioning Study With Antidepressants
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 347
- Enrollment target
NCT00316160: Completed Phase 4 study, sponsored by GlaxoSmithKline.
NCT00316160 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 347 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00316160, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 347 participants
- Enrollment target
Study Summary
Effects of two depression medication on sexual functioning
Interventions
- DRUG Bupropion Hydrochloride Extended-release
- DRUG Extended-release Venlafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
What the finished NCT00316160 record still lists
NCT00316160 is an interventional study that assigns participants to a tested intervention. The registered 347 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 2 interventions - of which Bupropion Hydrochloride Extended-release is the first listed.
NCT00316160 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00316160 about?
NCT00316160 is a clinical study titled "Sexual Functioning Study With Antidepressants". Effects of two depression medication on sexual functioning
What is the current status of trial NCT00316160?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 347 participants. The study started on 2004-09. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00316160?
The interventions under investigation include: Bupropion Hydrochloride Extended-release (DRUG), Extended-release Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT00316160?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00316160's enrollment target sits among peer trials
347 241st of 2000 higher than 1,759 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01742143 · 347 participants
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
- NCT04877522 · 347 participants · Phase 4
Asciminib Roll-over Study
- NCT05834660 · 347 participants · NA
SAFETY-A for Promoting Equity in Suicide Prevention Outcomes in Schools
- NCT06963827 · 347 participants · Phase 3
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia